NCT02895906已完成1 期
A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)
Aevi Genomic Medicine, LLC, a Cerecor company1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2016年11月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Time to symptom relapse
研究概览
简要总结
This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has a diagnosis of a 22q11.2 deletion prior to screening.
- •Subject has a diagnosis of anxiety disorder and/or ADHD and/or ASD based upon diagnostic evaluations performed at screening, history, and clinical judgement.
- •Subject is judged to be in general good health, other than having anxiety disorder and/or ADHD and/or ASD and 22q11DS. Medical conditions related to 22q11DS must be clinically stable post surgical correction and/or medical management.
- •Subject has no clinically significant abnormality on 12-lead electrocardiogram (ECG) performed at screening or baseline such as serious arrhythmia, bradycardia, tachycardia, cardiac conduction problems, or other abnormalities deemed to be a potential safety issue.
- •Subject and parent/legal guardian understand the study procedures and agree to the subject's participation in the study as indicated by parental/legal guardian signature on the subject informed consent form and subject's signature on the assent form.
排除标准
- •Subject has a diagnosis of co-morbid major psychiatric disorders (ie, aside from anxiety disorder, ADHD, and/or ASD), including major depression, bipolar disease, schizophrenia (or any psychotic disorder), and moderate or severe intellectual disability, which in the opinion of the investigator may interfere with the conduct of study evaluations.
- •Subject has an IQ < 65 as determined by the Wechsler Abbreviated Scale of Intelligence.
- •Subject has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by his/her participation in the study.
- •Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or disease which is not currently stable clinically. Subjects with a history of uncomplicated kidney stones may be enrolled in the study at the discretion of the investigator.
- •Subject has a history of stroke, chronic seizures, or other major neurological disorder which, in the opinion of the investigator, would interfere with the subject's ability to participate and/or be evaluated in the trial.
- •Subject is currently considered at risk for suicide (in the opinion of the investigator), has previously made a suicide attempt, or is currently demonstrating active suicidal ideation.
- •Subject has taken any antidepressants, antipsychotics, anxiolytics, or non-stimulant ADHD medication within 30 days of the Screening Visit.
- •Subject is taking a prohibited medication
研究组 & 干预措施
NFC-1
Experimental
Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
干预措施: NFC-1 (Drug)
结局指标
主要结局
Time to symptom relapse
时间窗: Through study completion, up to 5 weeks
次要结局
- Response to treatment based on Clinical Global Impression - Improvement scale(Through study completion, up to 5 weeks)
- Safety and tolerability as determined by AEs, laboratory results, C-SSRS, and K-SADS(Through study completion, up to 5 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)Allergic RhinoconjunctivitisChronic UrticariaNCT01081574Faes Farma, S.A.36
终止
3 期
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT01123707Otsuka Pharmaceutical Development & Commercialization, Inc.173
撤回
1 期
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 YearsChemotherapy Induced Nausea and VomitingNCT01596426Kyowa Kirin Pharmaceutical Development Ltd
进行中（未招募）
不适用
A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladderTreatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.MedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2008-004124-23-GBPfizer Limited326
已完成
1 期
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 YearsChemotherapy Induced Nausea and VomitingNCT01596400Kyowa Kirin Pharmaceutical Development Ltd19